News

Cardiovascular drugs are among the most widely used, since their indications are far reaching and address conditions that are prevalent among a large population.

Express Scripts will implement more programs that pay for drugs based on their effectiveness, according to the PBM’s chief medical officer Steve Miller, MD. Simultaneously, the PBM plans to implement a spending cap on diabetes medications.

Doug Chaet, senior vice president, Provider Networks and Value-Based Solutions at Independence Blue Cross, shares five strategies that can help providers succeed in value-based reimbursement models.

Democratic presidential candidate Hillary Clinton vows to provide more affordable, cost effective, accessible, and higher quality healthcare and insurance coverage. Here’s a closer look at seven key ways Clinton would change the healthcare system if elected president.

FDA approved the first drug to hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.

Drug coupons sound good on paper for both manufacturers who sell more products and for patients who pay less for a high-priced new product. But payers and pharmacy benefits managers are not impressed.

Hospitalizations represent up to 80 percent of the direct medical costs of heart failure; reducing heart failure hospitalizations can help bring down overall healthcare costs.

A look at how Trump's specific plans for healthcare could impact the industry.

The first US test for the Zika virus is available after Quest Diagnostics received an Emergency Use Authorization (EUA) for its Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test).

FDA recently approved a new indication for afatinib (Gilotrif, Boehringer Ingelheim) for patients with squamous cell carcinoma of the lung. The once-daily tablets are now indicated for the treatment of patients with the lung cancer, whose disease has progressed after treatment with platinum-based chemotherapy. Here are the top 6 facts to know about Gilotrif.

A look at how each GOP candidate’s specific plans for healthcare could impact the industry.

New regulations will check the drive to narrow networks, just as the business case for forming them grows more compelling.

Personalization is the key to a healthcare experience that optimizes outcomes, improves the customer experience and, ultimately, lowers costs to the healthcare system. Find out why it’s especially key for diabetic patients.

Mobile health (mHealth) offers new ways to empower patients with diabetes in caring for themselves and making decisions that support their health.

Democratic presidential candidates Bernie Sanders and Hillary Clinton both vow to make healthcare more affordable, accessible, and higher quality. Here’s a closer look at two of the ways Sanders proposes to do this.

Like any medication, benzodiazepines should be used with caution. However, the tremendous expenditure for these medications-just a year after Medicare Part D extended its coverage to include them in 2012-has some wondering why so many of these drugs are being prescribed.

FDA expanded the use of ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets without ribavirin (Viekira Pak, AbbVie) this week to treat patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A).

Some of the newest wearable devices on the market look very different than the wristbands that launched the industry just a few years ago.

The Leapfrog Group announced its Hospital Safety Scores, which gives hospitals a grade of “A” through “F” for patient safety.

After suffering significant losses on the health insurance exchanges in 2015, insurance giants UnitedHealth Group and Aetna announced they may leave the exchanges next year.

Staying compliant with a prescribed treatment regimen gives cardiovascular disease patients the best chance of improving their heart health and reducing future incidences of cardiac events. Here’s how to get patients on board.

A report from the Department of Health and Human Services indicates positive momentum in efforts to combat hospital-acquired conditions, but experts say more can be done.

A glimpse into the present and future of healthcare industry mergers and acquisitions

Surprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.

New analysis finds proposed Medicare payment changes for physician-administered drugs would reduce reimbursement for those that cost more than $480 per day in 2016. Seven of the 10 drugs that constitute the largest reduction in reimbursement are used to treat cancer.

Two presenters at the AMCP 2016 conference examine a Blue Cross and Blue Shield of Michigan pilot project to leverage technology for its medical specialty drug management program. Here are the lessons learned.

AMCP 2016 conference presenters from MedImpact outline their High-Cost Generic program that moves members to less-expensive, clinically relevant drug alternatives.